Aptinyx Inc., an Evanston, Ill.-based spinout of Allergan plc-acquired Naurex Inc., has completed a $65 million series A financing that will carry the company's lead candidate through initial clinical proof of concept in a yet-to-be chosen CNS indication, while also funding discovery in its specialty, small-molecule modulators of the N-methyl-D-aspartate (NMDA) receptor.